1. Home
  2. QLGN vs LGMK Comparison

QLGN vs LGMK Comparison

Compare QLGN & LGMK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QLGN
  • LGMK
  • Stock Information
  • Founded
  • QLGN 1996
  • LGMK 2011
  • Country
  • QLGN United States
  • LGMK United States
  • Employees
  • QLGN N/A
  • LGMK N/A
  • Industry
  • QLGN Biotechnology: Pharmaceutical Preparations
  • LGMK Industrial Specialties
  • Sector
  • QLGN Health Care
  • LGMK Health Care
  • Exchange
  • QLGN Nasdaq
  • LGMK Nasdaq
  • Market Cap
  • QLGN 3.2M
  • LGMK 3.5M
  • IPO Year
  • QLGN N/A
  • LGMK N/A
  • Fundamental
  • Price
  • QLGN $4.07
  • LGMK $1.41
  • Analyst Decision
  • QLGN
  • LGMK
  • Analyst Count
  • QLGN 0
  • LGMK 0
  • Target Price
  • QLGN N/A
  • LGMK N/A
  • AVG Volume (30 Days)
  • QLGN 20.7K
  • LGMK 304.5K
  • Earning Date
  • QLGN 11-14-2024
  • LGMK 11-12-2024
  • Dividend Yield
  • QLGN N/A
  • LGMK N/A
  • EPS Growth
  • QLGN N/A
  • LGMK N/A
  • EPS
  • QLGN N/A
  • LGMK N/A
  • Revenue
  • QLGN N/A
  • LGMK $10,078,502.00
  • Revenue This Year
  • QLGN N/A
  • LGMK $1.54
  • Revenue Next Year
  • QLGN N/A
  • LGMK N/A
  • P/E Ratio
  • QLGN N/A
  • LGMK N/A
  • Revenue Growth
  • QLGN N/A
  • LGMK 4.44
  • 52 Week Low
  • QLGN $3.34
  • LGMK $1.32
  • 52 Week High
  • QLGN $29.45
  • LGMK $32.25
  • Technical
  • Relative Strength Index (RSI)
  • QLGN 45.00
  • LGMK 38.44
  • Support Level
  • QLGN $3.95
  • LGMK $1.32
  • Resistance Level
  • QLGN $4.21
  • LGMK $1.49
  • Average True Range (ATR)
  • QLGN 0.27
  • LGMK 0.15
  • MACD
  • QLGN 0.00
  • LGMK 0.01
  • Stochastic Oscillator
  • QLGN 22.08
  • LGMK 20.79

About QLGN Qualigen Therapeutics Inc.

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

About LGMK LogicMark Inc. (NV)

LogicMark Inc provides personal emergency response systems (PERS), health communications devices, and IoT technologies to create a connected care platform. Its devices give people the ability to receive care at home and confidence to age in place. The company incorporates two-way voice communication technology directly into its medical alert pendant and provides this life-saving technology at a price point that everyday consumers can afford.

Share on Social Networks: